Minute Insight: Pear Gets FDA’s STeP Designation For Chronic Pain Therapeutic
Executive Summary
Pear Therapeutics is developing the Pear-010 digital therapeutic for virtual reality-delivered pain reduction in adults with acute postoperative and postprocedural pain. Its inclusion in FDA’s Safer Technologies Program (STeP) program suggests the FDA is committed to continuing that program for products that treat non-life-threatening or reversible conditions.
You may also be interested in...
Is Time Nearly Up For Pear? The PDT Company Could Be Bargain For Acquirer
Despite earlier efforts to restructure, the company is still struggling to meet its revenue targets, and issued a statement suggesting that further measures, including liquidation, may be necessary.
Minute Insight: OxfordVR’s Virtual Reality Program Treats Agoraphobia In Trial
Results of a 346-patient randomized trial run by the UK’s National Health Service showed the automated virtual reality system developed by researchers at Oxford University helped people with agoraphobia re-engage with day-to-day activities outside their home.
Minute Insight: Pear Therapeutics Inks Agreement With SoftBank To Develop Japan-Focused Digital Therapeutic
Pear Therapeutics signed an agreement with SoftBank to develop a Japan-focused digital therapeutic, but regulatory questions remain.